Salarius explores strategic alternatives, cuts workforce >50% after Q2 net loss of $3.9M

Decoy Therapeutics Inc.

FDA removed partial clinical hold on seclidemstat Phase 1/2 Ewing sarcoma trial.
SP-3164 received FDA IND clearance for relapsed/refractory NHL Phase 1 trial.
Cash $11.5M as of June 30, expected to fund operations through Q4 2023.
Net loss Q2 2023 was $3.9M ($1.43/share) vs $4.7M ($2.20/share) in Q2 2022.
Implementing cost-savings plan with >50% workforce reduction to extend resources.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.85

Decoy Therapeutics Inc. reported three and six months ended June 30, 2023 results: net income Net loss for the second quarter of 2023 was $3.9 million, or $1.43 per share, EPS $1.43 per share.

Period: three and six months ended June 30, 2023
Net income: Net loss for the second quarter of 2023 was $3.9 million, or $1.43 per share
EPS: $1.43 per share
Result: reported results

Exact text from the filing

reported financial results for the three and six months ended June 30, 2023

View on SEC.gov

Browse all earnings releases →

Decoy Therapeutics Inc. filing history →

Source: SEC EDGAR

accession 0001615219-23-000063

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.